MedTrace Logo

HD12 for Advanced Stages

NCT00265031 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-06-25

No results posted yet for this study

Summary

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

Conditions

  • Hodgkin´s Lymphoma

Interventions

DRUG

Cyclophosphamide

DRUG

Adriamycin

DRUG

Etoposide

DRUG

Procarbazine

DRUG

Prednisone

DRUG

Vincristine

DRUG

Bleomycin

PROCEDURE

radiation therapy

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Volker Diehl, Prof. · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265031 on ClinicalTrials.gov